Advanced search
Publication Cover
Immunotherapy Volume 3, 2011 - Issue 4
Submit an article Journal homepage
117
Views
0
CrossRef citations to date
0
Altmetric
Review

Is Antigen Specificity the Key to Efficient Adoptive T-Cell Therapy?

Nathalie Labarriere1 Unite Mixte de Recherche Institut National de la Sante et de la Recherche Medicale, Unite 892, Centre de Recherche en Canerologie Nantes-Angers, F-44007Nantes, FranceView further author information
,
Amir Khammari1 Unite Mixte de Recherche Institut National de la Sante et de la Recherche Medicale, Unite 892, Centre de Recherche en Canerologie Nantes-Angers, F-44007Nantes, France;2 Centre Hospitalo-Universitaire de Nantes, Unit of Skin Cancer, F-44093Nantes, FranceView further author information
,
Francois Lang1 Unite Mixte de Recherche Institut National de la Sante et de la Recherche Medicale, Unite 892, Centre de Recherche en Canerologie Nantes-Angers, F-44007Nantes, France;3 Université de Nantes, Unite de Formation et de Recherche des Sciences Pharmaceutiques, F-44093Nantes, FranceView further author information
&
Brigitte Dreno1 Unite Mixte de Recherche Institut National de la Sante et de la Recherche Medicale, Unite 892, Centre de Recherche en Canerologie Nantes-Angers, F-44007Nantes, France;2 Centre Hospitalo-Universitaire de Nantes, Unit of Skin Cancer, F-44093Nantes, FranceCorrespondence[email protected]
View further author information
Pages 495-505 | Published online: 04 Apr 2011

Bibliography

  • Balch CM , SoongSJ, GershenwaldJE et al.: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.J. Clin. Oncol.19(16) , 3622–3634 (2001).
  • Surman DR , DudleyME, OverwijkWW, RestifoNP: Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.J. Immunol.164(2) , 562–565 (2000).
  • Dunn GP , OldLJ, SchreiberRD: The immunobiology of cancer immunosurveillance and immunoediting.Immunity21(2) , 137–148 (2004).
  • Sato E , OlsonSH, AhnJ et al.: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.Proc. Natl Acad. Sci. USA102(51) , 18538–18543 (2005).
  • Zhang L , Conejo-GarciaJR, KatsarosD et al.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.N. Engl. J. Med.348(3) , 203–213 (2003).
  • Galon J , CostesA, Sanchez-CaboF et al.: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.Science313(5795) , 1960–1964 (2006).
  • Marrogi AJ , MunshiA, MerogiAJ et al.: Study of tumor infiltrating lymphocytes and transforming growth factor-β as prognostic factors in breast carcinoma.Int. J. Cancer74(5) , 492–501 (1997).
  • Clark WH Jr, Elder DE, Guerry DT et al.: Model predicting survival in stage I melanoma based on tumor progression. J. Natl Cancer Inst.81(24) , 1893–1904 (1989).
  • Clemente CG , MihmMC Jr, Bufalino R et al.: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer77(7) , 1303–1310 (1996).
  • Zippelius A , BatardP, Rubio-GodoyV et al.: Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.Cancer Res.64(8) , 2865–2873 (2004).
  • Matzinger P : The danger model: a renewed sense of self.Science296(5566) , 301–305 (2002).
  • Ochsenbein AF , SierroS, OdermattB et al.: Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction.Nature411(6841) , 1058–1064 (2001).
  • Shevach EM : CD4+ CD25+ suppressor T cells: more questions than answers.Nat. Rev. Immunol.2(6) , 389–400 (2002).
  • Khammari A , NguyenJM, PandolfinoMC et al.: Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma.Cancer Immunol. Immunother.56(11) , 1853–1860 (2007).
  • Vignard V , LemercierB, LimA et al.: Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells.J. Immunol.175(7) , 4797–4805 (2005).
  • June CH : Adoptive T cell therapy for cancer in the clinic.J. Clin. Invest.117(6) , 1466–1476 (2007).
  • Hunder NN , WallenH, CaoJ et al.: Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.N. Engl. J. Med.358(25) , 2698–2703 (2008).
  • Mazumder A , RosenbergSA: Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.J. Exp. Med.159(2) , 495–507 (1984).
  • Rosenberg SA , LotzeMT, MuulLM et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.N. Engl. J. Med.316(15) , 889–897 (1987).
  • Rosenberg SA , LotzeMT, MuulLM et al.: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.N. Engl. J. Med.313(23) , 1485–1492 (1985).
  • Rosenberg SA , PackardBS, AebersoldPM et al.: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.N. Engl. J. Med.319(25) , 1676–1680 (1988).
  • Dillman RO , OldhamRK, BarthNM et al.: Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial.Cancer68(1) , 1–8 (1991).
  • Goedegebuure PS , DouvilleLM, LiH et al.: Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.J. Clin. Oncol.13(8) , 1939–1949 (1995).
  • Jotereau F , PandolfinoMC, BoudartD et al.: High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy.J. Immunother.10(6) , 405–411 (1991).
  • Pandolfino MC , LabarriereN, TessierMH et al.: High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus: predictability and relation with disease advancement.Cancer Immunol. Immunother.50(3) , 134–140 (2001).
  • Dreno B , NguyenJM, KhammariA et al.: Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma.Cancer Immunol. Immunother.51(10) , 539–546 (2002).
  • Labarriere N , PandolfinoMC, GervoisN et al.: Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients.Cancer Immunol. Immunother.51(10) , 532–538 (2002).
  • Benlalam H , VignardV, KhammariA et al.: Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients.Cancer Immunol. Immunother.56(4) , 515–526 (2007).
  • Godet Y , Moreau-AubryA, GuillouxY et al.: MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency.J. Exp. Med.205(11) , 2673–2682 (2008).
  • Dudley ME , WunderlichJR, RobbinsPF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.Science298(5594) , 850–854 (2002).
  • Dudley ME , WunderlichJR, YangJC et al.: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.J. Clin. Oncol.23(10) , 2346–2357 (2005).
  • Robbins PF , DudleyME, WunderlichJ et al.: Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy.J. Immunol.173(12) , 7125–7130 (2004).
  • Zhou J , ShenX, HuangJ et al.: Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.J. Immunol.175(10) , 7046–7052 (2005).
  • Rosenberg SA ,Dudley ME: Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol.21(2) , 233–240 (2009).
  • Antony PA , PiccirilloCA, AkpinarliA et al.: CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.J. Immunol.174(5) , 2591–2601 (2005).
  • Gattinoni L , FinkelsteinSE, KlebanoffCA et al.: Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.J. Exp. Med.202(7) , 907–912 (2005).
  • Dudley ME , YangJC, SherryR et al.: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.J. Clin. Oncol.26(32) , 5233–5239 (2008).
  • Besser MJ , Shapira-FrommerR, TrevesAJ et al.: Clinical responses in a Phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.Clin. Cancer Res.16(9) , 2646–2655 (2010).
  • Sharkey MS , LizeeG, GonzalesMI, PatelS, TopalianSL: CD4+ T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation.Cancer Res.64(5) , 1595–1599 (2004).
  • Linard B , BezieauS, BenlalamH et al.: A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion.J. Immunol.168(9) , 4802–4808 (2002).
  • Robbins PF , El-GamilM, LiYF et al.: A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.J. Exp. Med.183(3) , 1185–1192 (1996).
  • De Smet C , LurquinC, LetheB, MartelangeV, BoonT: DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter.Mol. Cell. Biol.19(11) , 7327–7335 (1999).
  • Fijak M , MeinhardtA: The testis in immune privilege.Immunol. Rev.213 , 66–81 (2006).
  • Fiszer D , KurpiszM: Major histocompatibility complex expression on human, male germ cells: a review.Am. J. Reprod. Immunol.40(3) , 172–176 (1998).
  • van der Bruggen P , TraversariC, ChomezP et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.Science254(5038) , 1643–1647 (1991).
  • Chomez P , De Backer O, Bertrand M et al.: An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res.61(14) , 5544–5551 (2001).
  • Chen YT , ScanlanMJ, SahinU et al.: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.Proc. Natl Acad. Sci. USA94(5) , 1914–1918 (1997).
  • Lethe B , LucasS, MichauxL et al.: LAGE-1, a new gene with tumor specificity.Int. J. Cancer76(6) , 903–908 (1998).
  • Gure AO , WeiIJ, OldLJ, ChenYT: The SSX gene family: characterization of 9 complete genes.Int. J. Cancer101(5) , 448–453 (2002).
  • Chaux P , VantommeV, CoulieP, BoonT, van der Bruggen P: Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. Int. J. Cancer77(4) , 538–542 (1998).
  • Lonchay C , van der Bruggen P, Connerotte T et al.: Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl Acad. Sci. USA101(Suppl. 2) , 14631–14638 (2004).
  • Coulie PG , BrichardV, Van Pel A et al.: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med.180(1) , 35–42 (1994).
  • Kawakami Y , EliyahuS, DelgadoCH et al.: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.Proc. Natl Acad. Sci. USA91(9) , 3515–3519 (1994).
  • Brichard V , Van Pel A, Wolfel T et al.: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med.178(2) , 489–495 (1993).
  • Bakker AB , SchreursMW, de Boer AJ et al.: Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med.179(3) , 1005–1009 (1994).
  • Godet Y , DesfrancoisJ, VignardV et al.: Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy.Eur. J. Immunol.40(6) , 1786–1794 (2010).
  • Pittet MJ , ZippeliusA, ValmoriD et al.: Melan-A/MART-1-specific CD8 T cells: from thymus to tumor.Trends Immunol.23(7) , 325–328 (2002).
  • Zippelius A , PittetMJ, BatardP et al.: Thymic selection generates a large T cell pool recognizing a self-peptide in humans.J. Exp. Med.195(4) , 485–494 (2002).
  • Linehan DC , GoedegebuurePS, PeoplesGE, RogersSO, EberleinTJ: Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.J. Immunol.155(9) , 4486–4491 (1995).
  • Ikeda H , LetheB, LehmannF et al.: Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor.Immunity6(2) , 199–208 (1997).
  • Griffioen M , KesslerJH, BorghiM et al.: Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.Clin. Cancer Res.12(10) , 3130–3136 (2006).
  • Quintarelli C , DottiG, AngelisB: Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.Blood112(5) , 1876–1885 (2008).
  • Rezvani K , YongAS, TawabA: Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.Blood113(10) , 2245–2255 (2009).
  • Mackensen A , MeidenbauerN, VoglS et al.: Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.J. Clin. Oncol.24(31) , 5060–5069 (2006).
  • Meidenbauer N , MarienhagenJ, LaumerM et al.: Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients.J. Immunol.170(4) , 2161–2169 (2003).
  • Dudley ME , WunderlichJ, NishimuraMI et al.: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.J. Immunother.24(4) , 363–373 (2001).
  • Khammari A , LabarriereN, VignardV et al.: Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones.J. Invest. Dermatol.129(12) , 2835–2842 (2009).
  • Yee C , ThompsonJA, ByrdD et al.: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.Proc. Natl Acad. Sci. USA99(25) , 16168–16173 (2002).
  • Dudley ME , WunderlichJR, YangJC et al.: A Phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.J. Immunother.25(3) , 243–251 (2002).
  • Effros RB , PawelecG: Replicative senescence of T cells: does the Hayflick limit lead to immune exhaustion?Immunol. Today18(9) , 450–454 (1997).
  • Gattinoni L , PowellDJ Jr, Rosenberg SA, Restifo NP: Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol.6(5) , 383–393 (2006).
  • Hinrichs CS , GattinoniL, RestifoNP: Programming CD8+ T cells for effective immunotherapy.Curr. Opin. Immunol.18(3) , 363–370 (2006).
  • Menzel O , MigliaccioM, GoldsteinDR et al.: Mechanisms regulating the proliferative potential of human CD8+ T lymphocytes overexpressing telomerase.J. Immunol.177(6) , 3657–3668 (2006).
  • Schumacher TN : T-cell-receptor gene therapy.Nat. Rev. Immunol.2(7) , 512–519 (2002).
  • Dembic Z , HaasW, WeissS et al.: Transfer of specificity by murine α and β T-cell receptor genes.Nature320(6059) , 232–238 (1986).
  • Clay TM , CusterMC, Sachs et al.: Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol.1163(1) , 507–513 (1999).
  • Calogero A , HospersGA, KruseKM et al.: Retargeting of a T cell line by anti MAGE-3/HLA-A2 α β TCR gene transfer.Anticancer Res.20(3A) , 1793–1799 (2000).
  • Fujio K , MisakiY, SetoguchiK et al.: Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the α β TCR complex.J. Immunol.165(1) , 528–532 (2000).
  • Stanislawski T , VossRH, LotzC et al.: Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.Nat. Immunol.2(10) , 962–970 (2001).
  • Morgan RA , DudleyME, WunderlichJR et al.: Cancer regression in patients after transfer of genetically engineered lymphocytes.Science314(5796) , 126–129 (2006).
  • Cohen CJ , LiYF, El-GamilM et al.: Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.Cancer Res.67(8) , 3898–3903 (2007).
  • Cohen CJ , ZhaoY, ZhengZ, RosenbergSA, MorganRA: Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.Cancer Res.66(17) , 8878–8886 (2006).
  • Kuball J , DossettML, WolflM et al.: Facilitating matched pairing and expression of TCR chains introduced into human T cells.Blood109(6) , 2331–2338 (2007).
  • Bialer G , Horovitz-FriedM, Ya‘acobi et al.: Selected murine residues endow human TCR with enhanced tumor recognition. J. Immunol.184(11) , 6232–6241 (2010).
  • Chinnasamy N , WargoJA, YuZ, Rao et al.: A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J. Immunol.186(2) , 685–696 (2011).
  • Eshhar Z : Tumor-specific T bodies: towards clinical application.Cancer Immunol. Immunother.45(3–4) , 131–136 (1997).
  • Jena B , DottiG, CooperLJN: Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.Blood116(7) , 1035–1044 (2010).
  • Cobbold M , KhanN, PourgheysariB et al.: Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers.J. Exp. Med.202(3) , 379–386 (2005).
  • Bodinier M , PeyratMA, TournayC et al.: Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding.Nat. Med.6(6) , 707–710 (2000).
  • Labarriere N , GervoisN, BonninA et al.: PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting.Cancer Immunol. Immunother.57(2) , 185–195 (2008).
  • Bouquie R , BonninA, BernardeauK et al.: A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes.Cancer Immunol. Immunother.58(4) , 553–566 (2009).
  • Gao FG , KhammanivongV, LiuWJ et al.: Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell.Cancer Res.62(22) , 6438–6441 (2002).
  • Hu HM , WinterH, UrbaWJ, FoxBA: Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.J. Immunol.165(8) , 4246–4253 (2000).
  • Hung K , HayashiR, Lafond-WalkerA et al.: The central role of CD4+ T cells in the antitumor immune response.J. Exp. Med.188(12) , 2357–2368 (1998).
  • Keene JA , FormanJ: Helper activity is required for the in vivo generation of cytotoxic T lymphocytes.J. Exp. Med.155(3) , 768–782 (1982).
  • Castellino F , GermainRN: Cooperation between CD4+ and CD8+ T cells: when, where, and how.Annu. Rev. Immunol.24 , 519–540 (2006).
  • Toes RE , OssendorpF, OffringaR, MeliefCJ: CD4 T cells and their role in antitumor immune responses.J. Exp. Med.189(5) , 753–756 (1999).
  • Schietinger A , PhilipM, LiuRB, SchreiberK, SchreiberH: Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase.J. Exp. Med.207(11) , 2469–2477 (2010).
  • Quezada SA , SimpsonTR, PeggsKS et al.: Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.J. Exp. Med.207(3) , 637–650 (2010).
  • Chambers CA , KuhnsMS, EgenJG, AllisonJP: CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.Annu. Rev. Immunol.19 , 565–594 (2001).
  • Attia P , PhanGQ, MakerAV et al.: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.J. Clin. Oncol.23(25) , 6043–6053 (2005).
  • Sanderson K , ScotlandR, LeeP et al.: Autoimmunity in a Phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.J. Clin. Oncol.23(4) , 741–750 (2005).
  • Whiteside TL : Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.Expert Opin. Biol. Ther.10(7) , 1019–1035 (2010).
  • Koike N , Pilon-ThomasS,Mule JJ: Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma. J. Immunother.31(4) , 402–412 (2008).
  • Zhang B , BowermanNA, SalamaJK et al.: Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.J. Exp. Med.204(1) , 49–55 (2007).
  • Vo DD , PrinsRM, BegleyJL et al.: Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.Cancer Res.69(22) , 8693–8699 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.